8,882
Total Claims
$1.7M
Drug Cost
1,006
Beneficiaries
$1,702
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+12%
Cost per patient vs peers
$1,702 vs $1,524 avg
+9%
Brand preference vs peers
14.9% vs 13.7% avg
Brand vs Generic
85% generic
Brand: 1,320 claims · $1.5M
Generic: 7,562 claims · $184K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 389 | $490K |
| Dapagliflozin Propanediol | 232 | $301K |
| Rivaroxaban | 213 | $244K |
| Sacubitril/Valsartan | 148 | $205K |
| Empagliflozin | 63 | $84K |
| Alirocumab | 63 | $72K |
| Evolocumab | 32 | $49K |
| Atorvastatin Calcium | 1,518 | $25K |
| Rosuvastatin Calcium | 818 | $25K |
| Dabigatran Etexilate Mesylate | 35 | $17K |
| Icosapent Ethyl | 12 | $13K |
| Metoprolol Succinate | 549 | $13K |
| Icosapent Ethyl | 23 | $12K |
| Ezetimibe | 260 | $9,800 |
| Carvedilol | 455 | $7,208 |
Prescribing Profile
54
Unique Drugs
$1.3M
Patient Profile
77
Avg Age
55%
Female
1.40
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data